PP2A-Regulated Autophagy Drives Drug Resistance in Candida albicans Biofilms

Study Background and Research Question

Candida albicans is a ubiquitous opportunistic fungal pathogen responsible for a range of infections, from superficial mucosal disease to life-threatening invasive candidiasis. A critical factor in its virulence and persistence is its ability to form biofilms—structured microbial communities that adhere to surfaces and display heightened resistance to antifungal agents. The increasing emergence of drug-resistant C. albicans biofilms presents a formidable clinical challenge, especially as the arsenal of effective antifungal drugs remains limited.

While the molecular basis of antifungal resistance in biofilms is complex, recent attention has turned to autophagy, a conserved eukaryotic process for intracellular degradation and recycling. Autophagy is implicated in fungal adaptation under stress, yet its direct role in biofilm drug resistance has not been fully elucidated. The present study (Shen et al., 2025) addresses whether the serine/threonine phosphatase protein phosphatase 2A (PP2A) impacts biofilm formation and antifungal resistance in C. albicans through autophagy induction, and further investigates the molecular mechanism underlying this regulation.

Key Innovation from the Reference Study

The central innovation of this work is the identification of a mechanistic link between PP2A activity, autophagy regulation via ATG protein phosphorylation, and the resultant drug resistance phenotype in C. albicans biofilms. Specifically, the study demonstrates that PP2A modulates the phosphorylation status of Atg13, leading to activation of Atg1 and subsequent autophagy induction. This axis promotes biofilm formation and enhances resistance to antifungal agents. Conversely, genetic disruption of the PP2A catalytic subunit gene (PPH21) impairs autophagy activation and increases biofilm susceptibility to antifungal therapy, thus pinpointing PP2A as a potential target for overcoming biofilm-associated drug resistance.

Methods and Experimental Design Insights

The study employs a multifaceted experimental approach:

• Gene Expression Analysis: Expression of the PPH21 gene encoding the PP2A catalytic subunit was quantified in wild-type and mutant strains.
• Mutant Construction: A pph21Δ/Δ knockout strain was generated to assess the functional contribution of PP2A.
• Autophagy Modulation: Rapamycin, a well-established autophagy activator, was used to stimulate autophagic activity in biofilms of both wild-type and mutant strains.
• Biofilm and Drug Susceptibility Assays: Biofilm formation was quantified, and susceptibility to antifungal agents, notably azoles, was tested in vitro.
• Oxidative Stress Measurements: Levels of oxidative stress were measured to evaluate the interplay between autophagy, stress response, and drug resistance.
• Autophagosome Visualization: Autophagic flux was assessed via detection of autophagosomes by fluorescence microscopy and biochemical markers.
• In Vivo Model: The therapeutic efficacy of antifungal agents was evaluated in a mouse model of oral C. albicans infection, comparing wild-type and pph21Δ/Δ strains under autophagy-activating conditions.

Protocol Parameters

• PPH21 knockout construction: Employ homologous recombination to delete both alleles of PPH21 in C. albicans for functional analysis.
• Autophagy activation: Treat biofilms with rapamycin (concentration per established autophagy protocols) to stimulate autophagic flux prior to drug susceptibility testing.
• Biofilm antifungal challenge: Apply azole antifungal agents, such as fluconazole, at concentrations relevant to clinical resistance thresholds (e.g., 10 μg/mL for in vitro susceptibility, see product information).
• In vivo infection model: Infect immunocompromised mice orally with wild-type or knockout strains; administer antifungal therapy intraperitoneally at established dosages (e.g., fluconazole 80 mg/kg/day).
• Autophagic activity assessment: Use fluorescent markers for autophagosome detection and immunoblotting for Atg protein levels.

Core Findings and Why They Matter

Shen et al. (2025) provide compelling evidence that PP2A is a critical regulator of autophagy-mediated drug resistance in C. albicans biofilms. Key findings include:

• PPH21 Expression Correlates with Biofilm Drug Resistance: Elevated expression of PPH21 is associated with increased biofilm formation and higher resistance to antifungal agents.
• Autophagy Activation Promotes Resistance: Pharmacological stimulation of autophagy with rapamycin enhances biofilm resilience and drug tolerance, while the pph21Δ/Δ mutant fails to mount this protective effect.
• ATG Protein Phosphorylation as the Regulatory Node: Loss of PP2A activity disrupts Atg13 phosphorylation, impeding subsequent Atg1 activation and downstream autophagic flux.
• Therapeutic Implications in Vivo: In a murine oral infection model, biofilms formed by the pph21Δ/Δ mutant are more susceptible to antifungal therapy, suggesting that targeting PP2A-autophagy could resensitize biofilms to drugs like fluconazole.

These results underscore that autophagy, controlled at the level of protein phosphorylation by PP2A, is a key determinant of biofilm-associated drug resistance. This insight points to novel intervention strategies beyond traditional ergosterol biosynthesis inhibitors, emphasizing the potential of PP2A or autophagy pathway modulation to enhance antifungal efficacy.

Comparison with Existing Internal Articles

Current internal resources, such as "Disrupting the Fortress: Mechanistic and Strategic Advances", highlight the centrality of fluconazole as a fungal cytochrome P450 enzyme 14α-demethylase inhibitor targeting ergosterol biosynthesis. These articles discuss how biofilm-mediated resistance complicates treatment and examine the utility of fluconazole in both in vitro and in vivo models. However, Shen et al. (2025) extend this body of knowledge by identifying autophagy induction as a pivotal mechanism by which biofilms gain resistance, independent of direct drug-target interactions. This perspective is echoed in "Fluconazole as a Strategic Lever in Fungal Pathogenesis Research", which notes the emerging importance of autophagy and protein phosphorylation in drug-resistant biofilms, but the reference study provides direct experimental evidence linking these processes.

Collectively, these resources position fluconazole as a benchmark compound for antifungal susceptibility testing and candidiasis model optimization, while the new findings suggest that combining azole therapy with autophagy pathway inhibitors could be a future research direction.

Limitations and Transferability

Several limitations warrant consideration:

• Model Specificity: The focus on oral biofilm models may not fully capture the complexity of systemic candidiasis or non-oral biofilm environments.
• Genetic Redundancy: PP2A is part of a larger phosphatase network; potential compensatory mechanisms in other strains or species may limit direct translational applicability.
• Pharmacological Tools: While rapamycin is a well-established autophagy activator, its effects on other cellular pathways could confound interpretations.
• Clinical Translation: Targeting PP2A or autophagy in patients may face toxicity or specificity challenges, requiring further validation in diverse host-pathogen settings.

Nonetheless, the mechanistic clarity provided by this study lays a strong foundation for future research into antifungal drug resistance mechanisms and potential combinatorial therapies in fungal pathogens.

Research Support Resources

To experimentally validate and extend these findings, researchers require reliable tools for antifungal susceptibility testing and biofilm model development. Fluconazole (SKU B2094) from APExBIO remains a standard triazole antifungal for such workflows, with documented efficacy against C. albicans biofilms and applications in both in vitro and in vivo models. Its well-characterized activity as a fungal cytochrome P450 enzyme 14α-demethylase inhibitor and ergosterol biosynthesis disruptor supports reproducibility in antifungal drug resistance research, as highlighted in recent internal articles. For protocol optimization, refer to the product's dissolution and storage guidelines to ensure experimental consistency. This research-grade compound is intended for scientific use only and is not for clinical application.